TMCnet News

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of Investors
[January 19, 2023]

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of Investors


Law Offices of Howard G. Smith announces an investigation on behalf of Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) investors concerning the Company's possible violations of federal securities laws.

On April 1, 2022, the Company announced that it had resubmitted its Biologics License Application ("BLA") for omburtamab for the treatment of pediatric patients with CNS from neuroblastoma, following several meetings with the U.S. Food and Drug Administration ("FDA") to address deficiencies identified in the agency's 2020 refusal to file letter in response to Y-mAbs's previous BLA.

On October 26, 2022, the FDA released its briefing documnt in advance of its Advisory Committee meeting to discuss the omburtamab BLA. The briefing document identified three key issues regarding the submitted data, which led analysts to conclude that Y-mAbs had resubmitted the BLA prior to reaching agreement with the FDA regarding the content of the application.



On this news, Y-mAbs's stock price fell $4.16, or 27.4%, to close at $11.01 per share on October 26, 2022, thereby injuring investors.

If you purchased Y-mAbs securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.


This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


[ Back To TMCnet.com's Homepage ]